The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The country with the third largest HIV epidemic moves to a test-and-treat strategy that aims to get everyone on antiretroviral therapy.
The first trials enhancing orally-taken antiretroviral treatment with Solid Drug Nanoparticle technology have produced “incredibly promising” results.
The first ever study evaluating the decentralising of HIV care through antiretroviral treatment (ART) distribution centres shows low rates of patient loss in the city.
‘Surprising’ research from Conference on Retroviruses and Opportunistic Infections (CROI) shows drug resistance does not impact test-and-treat roll-out in South Africa – at least in the short term.
Mixed-status couples using PrEP could benefit from HIV self-testing as a way to quickly diagnose any new infections and reduce frequency of clinic visits.
Identifying individuals at high risk of disengaging with HIV care remains an important strategy for realising the benefits of antiretroviral treatment for public health.
HIV is more proactively monitored among urban HIV patients than rural patients, and drug resistance and treatment failure is less prevalent. However outcomes for second line treatment remain similar.
Treatment scale-up has had major public health benefits. But where resources are scarce, interventions to keep people in care could be more cost-effective than moving to treat everybody living with HIV after diagnosis.
With 17 million people now accessing antiretroviral treatment worldwide, HIV drug resistance has the potential to unravel progress towards the Fast-Track target of ending AIDS by 2030.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.